Current techniques in reprogramming cell potency

Romli, Firdaus; Alitheen, Noorjahan Banu; Hamid, Muhajir; Ismail, Ruzila; Rahman, Nik Mohd Afizan Nik Abd

doi:10.1002/jcb.24477

Cited by 5 publications

(2 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the epithelialmesenchymal transition (EMT) process has emerged as an important mode of metastatic potential. EMT can also be defined as a series of well-coordinated changes in which cells become immobile and strongly connected to the adjacent extracellular matrix (ECM), resulting in changes in FA metabolism [ 47 , 48 ]. Tumour cells with a mesenchymal phenotype and epithelial-mesenchymal phenotypic plasticity are more effective in circulating and priming for secondary site colonisation and metastatic formation [ 49 ].…”

Section: Molecular Mechanisms Of Fatty Acid Metabolism In Cancer Meta...mentioning

confidence: 99%

Crosstalk between Fatty Acid Metabolism and Tumour-Associated Macrophages in Cancer Progression

Zaidi¹,

Shazali²,

Leow³

et al. 2022

BioMedicine

View full text Add to dashboard Cite

Summary Over the last few decades, cancer has been regarded as an independent and self sustaining progression. The earliest hallmarks of cancer comprise of sustaining proliferative signalling, avoiding growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. Nonetheless, two emerging hallmarks are being described: aberrant metabolic pathways and evasion of immune destruction. Changes in tumour cell metabolism are not restricted to tumour cells alone; the products of the altered metabolism have a direct impact on the activity of immune cells inside the tumour microenvironment, particularly tumour-associated macrophages (TAMs). The complicated process of cancer growth is orchestrated by metabolic changes dictating the tight mutual connection between these cells. Here, we discuss approaches to exploit the interaction of cancer cells’ abnormal metabolic activity and TAMs. We also describe ways to exploit it by reprogramming fatty acid metabolism via TAMs.

show abstract

Section: Molecular Mechanisms Of Fatty Acid Metabolism In Cancer Meta...mentioning

confidence: 99%

Crosstalk between Fatty Acid Metabolism and Tumour-Associated Macrophages in Cancer Progression

Zaidi¹,

Shazali²,

Leow³

et al. 2022

BioMedicine

View full text Add to dashboard Cite

show abstract

“…Generation of pluripotent human iPSCs from somatic cells was initially demonstrated by exogenous transgene expression of Oct4 , Sox2 , Kif4 , and c‐Myc or Oct4 , Sox2 , Nanog , and Lin 28 using retroviral and lentiviral vectors (Takahashi et al, ; Warren et al, ; Miyoshi et al, ; Polo et al, ). These reproducible transgenic approaches, have limited clinical application since the long‐term safety of genetically modified human cells has not been established (Grabel, ; Rao and Malik, ; Sommer and Mostoslavsky, ; Romli et al, ; Ma et al, ; Romano et al, ). While transient transfection of mRNAs and microRNAs (miRs) to generate iPSCs is compatible for clinical applications (Kuo and Ying, ; Soyombo et al, ) adoption of iPSCs for regenerative medicine has been slow to progress, as the methods to drive differentiation of iPSCs into specific cell types are not completely identified (Ma et al, ), and the safety and efficacy of transplanted iPSC‐derived tissues are being assessed.…”

mentioning

confidence: 99%

RNA‐Generated and Gene‐Edited Induced Pluripotent Stem Cells for Disease Modeling and Therapy

Kehler

Greco

Martino

et al. 2016

Journal Cellular Physiology

View full text Add to dashboard Cite

Cellular reprogramming by epigenomic remodeling of chromatin holds great promise in the field of human regenerative medicine. As an example, human-induced Pluripotent Stem Cells (iPSCs) obtained by reprograming of patient somatic cells are sufficiently similar to embryonic stem cells (ESCs) and can generate all cell types of the human body. Clinical use of iPSCs is dependent on methods that do not utilize genome altering transgenic technologies that are potentially unsafe and ethically unacceptable. Transient delivery of exogenous RNA into cells provides a safer reprogramming system to transgenic approaches that rely on exogenous DNA or viral vectors. RNA reprogramming may prove to be more suitable for clinical applications and provide stable starting cell lines for gene-editing, isolation, and characterization of patient iPSC lines. The introduction and rapid evolution of CRISPR/Cas9 gene-editing systems has provided a readily accessible research tool to perform functional human genetic experiments. Similar to RNA reprogramming, transient delivery of mRNA encoding Cas9 in combination with guide RNA sequences to target specific points in the genome eliminates the risk of potential integration of Cas9 plasmid constructs. We present optimized RNA-based laboratory procedure for making and editing iPSCs. In the near-term these two powerful technologies are being harnessed to dissect mechanisms of human development and disease in vitro, supporting both basic, and translational research. J. Cell. Physiol. 232: 1262-1269, 2017. © 2016 Wiley Periodicals, Inc.

show abstract

Cells for Tissue Engineering

Birla

2014

Introduction to Tissue Engineering

View full text Add to dashboard Cite

Current techniques in reprogramming cell potency

Cited by 5 publications

References 60 publications

Crosstalk between Fatty Acid Metabolism and Tumour-Associated Macrophages in Cancer Progression

Crosstalk between Fatty Acid Metabolism and Tumour-Associated Macrophages in Cancer Progression

RNA‐Generated and Gene‐Edited Induced Pluripotent Stem Cells for Disease Modeling and Therapy

Cells for Tissue Engineering

Contact Info

Product

Resources

About